Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Insight Molecular Diagnostics Inc.OCX · Entity 6631 | VP of Marketing | June 07, 2018 | June 11, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Insight Molecular Diagnostics Inc.
Report date June 07, 2018 · Filed June 11, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.85 · Expires 2028-06-06 | Direct | 50,000 |
Reported balance
After 2018-06-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-07 · Grant · Acquired 50,000 · Balance 50,000 F1: One half of these options shall vest on the filing of the Medicare dossier for the Medicare local coverage determination for OncoCyte's DetermaVu product candidate, subject to continuous employment on such date, and the balance shall vest on the date of return from sabbatical and obtaining a Medicare local coverage determination for OncoCyte's DetermaVu product candidate, subject to continuous employment on such date. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.35 · Expires 2028-05-22 | Direct | 125,000 |
Reported balance
Holding disclosure · report date 2018-06-07 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 125,000 F2: These options vest as to one-third of the shares on each of the completion of the clinical utility study for OncoCyte's DetermaVu product candidate, the filing of the Medicare dossier for the Medicare local coverage determination, and obtaining a Medicare local coverage determination for OncoCyte's DetermaVu product candidate. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $4.70 · Expires 2027-02-16 | Direct | 67,500 |
Reported balance
Holding disclosure · report date 2018-06-07 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 67,500 F3: One quarter of the options vested on February 16, 2018, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $3.06 · Expires 2026-02-15 | Direct | 60,000 |
Reported balance
Holding disclosure · report date 2018-06-07 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 60,000 F4: One quarter of the options vested on February 15, 2017, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $3.16 · Expires 2025-08-03 | Direct | 100,000 |
Reported balance
Holding disclosure · report date 2018-06-07 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 100,000 F5: One quarter of the options vested on August 3, 2016, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment. |
Filing footnotes · ownership attribution and instrument terms
F1: One half of these options shall vest on the filing of the Medicare dossier for the Medicare local coverage determination for OncoCyte's DetermaVu product candidate, subject to continuous employment on such date, and the balance shall vest on the date of return from sabbatical and obtaining a Medicare local coverage determination for OncoCyte's DetermaVu product candidate, subject to continuous employment on such date.
F2: These options vest as to one-third of the shares on each of the completion of the clinical utility study for OncoCyte's DetermaVu product candidate, the filing of the Medicare dossier for the Medicare local coverage determination, and obtaining a Medicare local coverage determination for OncoCyte's DetermaVu product candidate.
F3: One quarter of the options vested on February 16, 2018, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment.
F4: One quarter of the options vested on February 15, 2017, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment.
F5: One quarter of the options vested on August 3, 2016, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 07, 2018 Filed Jun 11, 2018 23:31 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 50,000 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0001209191-18-037121 · doc4.xml · derivative · entry 1 MECHEM KRISTINE C. · CIK 0001662454 · VP of Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-06-06 F1 · derivative.exercise_date: One half of these options shall vest on the filing of the Medicare dossier for the Medicare local coverage determination for OncoCyte's DetermaVu product candidate, subject to continuous employment on such date, and the balance shall vest on the date of return from sabbatical and obtaining a Medicare local coverage determination for OncoCyte's DetermaVu product candidate, subject to continuous employment on such date. Read SEC document |
| May 23, 2018 Filed Jun 5, 2018 00:55 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 125,000 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001209191-18-035407 · doc4.xml · derivative · entry 1 MECHEM KRISTINE C. · CIK 0001662454 · VP of Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2028-05-22 F1 · derivative.exercise_date: These options vest as to one-third of the shares on each of the completion of the clinical utility study for OncoCyte's DetermaVu product candidate, the filing of the Medicare dossier for the Medicare local coverage determination, and obtaining a Medicare local coverage determination for OncoCyte's DetermaVu product candidate. Read SEC document |
| February 17, 2017 Filed Feb 23, 2017 02:54 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 67,500 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001209191-17-013575 · doc4.xml · derivative · entry 1 MECHEM KRISTINE C. · CIK 0001662454 · VP of Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,500 Underlying: Common Stock · 67,500 shares Expires 2027-02-16 F1 · derivative.exercise_date: One quarter of the options shall vest on February 16, 2018, subject to the completion of 12 months of continuous employment from the date of grant, and the balance shall vest in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.